Discovery and management of adverse drug reactions: The nomifensine hypersensitivity syndrome, 1977-1986

Social History of Medicine

Volumn 23, Issue 1, 2010, Pages 153-173

  Abraham, John ^b   Davis, Courtney ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b NONE

Author keywords

CSM; Drug safety; FDA; Pharmaceutical industry; Regulatory agencies

Indexed keywords

EID: 77950531315     PISSN: 0951631X     EISSN: 14774666     Source Type: Journal    
DOI: 10.1093/shm/hkp049     Document Type: Article

References (75)

1. Abraham J. 1995, Science, Politics and the Pharmaceutical Industry, London: UCL Press.
2. Abraham J. and Davis C. 2006, 'Testing Times: The Emergence of the Practolol Disaster and its Challenge to British Drug Regulation in the Modern Period', Social History of Medicine, 19, 127-147 (Pubitemid 43515506)
3. Abraham J. and Davis C. 2007, 'Deficits, Expectations and Paradigms in British and American Drug Safety Assessment', Science, Technology and Human Values, 32, 399-431.
4. Abraham J. and Lewis G. 2000, Regulating Medicines in Europe, London: Routledge.
5. Abraham J. and Sheppard J. 1999, The Therapeutic Nightmare: The Battle over the World's most Controversial Sleeping Pill, London: Earthscan.
6. Anon. 1985, 'Nomifensine UK Data Sheet Change', Scrip: World Pharmaceutical News, 1047, 23.
7. Anon. 1986a, 'Hoechst Withdraws Nomifensine', Scrip: World Pharmaceutical News, 1072, 22-23
8. Anon. 1986b, 'New Nomifensine UK Data Sheet', Scrip: World Pharmaceutical News, 1070, 23-24
9. Anon. 1990, 'Hoescht Agrees to US Fine over Merital', Scrip: World Pharmaceutical News, 1576, 8.
10. Anon. 1991, 'Hoescht Settles on US Merital', Scrip: World Pharmaceutical News, 1613, 14-15.
11. Anon. 1992, 'Adverse Drug Reaction (ADR) moves in Germany', Scrip: World Pharmaceutical News, 1681, 6-7.
12. Apfel R. J. and Fisher S. M. 1984, To Do No Harm: DES and the Dilemmas of Modern Medicine, New Haven: Yale University Press.
13. Bournerias F. and Habibi B. 1979, 'Nomifensine-Induced Immune Haemolytic Anaemia and Impaired Renal Function', Lancet, 14 July, 95-96 (Pubitemid 9223955)
14. Bud R. 2007, Penicillin: Triumph and Tragedy, Oxford: Oxford University Press.
15. Church R. and Tansey E. M. 2007, Burroughs Wellcome and Co.: Knowledge, Trust, Profit and the Transformation of the British Pharmaceutical Industry 1880-1940, Lancaster: Crucible Books.
16. Cole J. W. 1980, 'Nomifensine', FDA Review and Evaluation of Clinical Data, 12 August.
17. Committee on Safety of Medicines 1985, 'CSM Update: Adverse Reactions to Antidepressants', British Medical Journal, 7 December, 291, 1638.
18. Committee on Safety of Medicines 1986, 'CSM Update:Withdrawal of Nomifensine', British Medical Journal, 5 July, 293, 41.
19. Daemmrich A. A. 2004, Pharmacopolitics: Drug Regulation in the United States and Germany, Chapel Hill: University of North Carolina Press.
20. Dankbaar H. and Mudde A. H. 1980, 'Koorts en Leverfunctiestoornissen ten Gevolge van Nomifensine', Nederlands Tijdschrift Voor Geneeskunde, 124, 2184-2186
21. Eckstein R., Reiss H., Sauer H. and Mempel W. 1981, 'Nomifensine-Induced Immune Haemolytic Anaemias', Klinische Wochenschrift, 59, 567-569
22. Edwards J. G. 1997, 'Withdrawal of Psychotropic Drugs from the Market: II. From Nomifensine to Remoxipride', in Hindmarch I. and Stonier P. D. (eds), Human Pharmacology. Measures and Methods Volume6, Chichester: John Wiley and Sons, 215-233
23. Grant N. J. 1992, The Selling of Contraception: The Dalkon Shield Case, Sexuality, and Women's Autonomy, Columbus: Ohio State University Press.
24. Greene J. A. 2007, Prescribing by Numbers, Baltimore: Johns Hopkins University Press.
25. Healy D. 1997, The Anti-Depressant Era, Cambridge: Harvard University Press.
26. Healy D. 2004, Let Them Eat Prozac, New York: New York University Press.
27. Hoescht 1977, Merital Product Data Sheet.
28. Hoescht 1980, Merital Product Data Sheet.
29. Hoescht 1981, Merital Product Data Sheet.
30. Hoescht 1982-4, Merital Product Data Sheets.
31. Hoescht 1985, Merital Product Data Sheet.
32. Hoescht-Roussel 1985a, Merital (US label), January Edition.
33. Hoescht-Roussel 1985b, Merital (US label), November Edition.
34. Hoffman I. 1977, 'A Comparative Review of the Pharmacology of Nomifensine', British Journal of Clinical Pharmacology, 4, 69S-75S.
35. Hunziker T. H., Fehlmann U., Kummer H., Spengler H. and Hoigne R. 1980, 'Arzneifieber auf das Antidepressivum Nomifensin', Schweiz. med. Wschr., 110, 1295-1300 (Pubitemid 10040852)
36. Inman B. 1999, Don't Tell the Patient, Hampshire: Highland Park Productions.
37. Jones E. 2001, The Business of Medicine, London: Profile Books.
38. Keating P. and Cambrosio A. 2007, 'Cancer Clinical Trials', Bulletin for the History of Medicine, 81, 197-223.
39. Leber P. 1983, FDA Memo, Telephone Conversation with Dr John Griffin, UK Medicines Division, 5 November.
40. Leber P. 1984a, A Memo, 'Nomifensine's Risks and its Final Approved Labelling', 28 December.
41. Leber P. 1984b, FDA Letter from Paul Leber to Hoescht-Roussel, 1 August.
42. Lesch J. E. 2007, The First Miracle Drugs, New York: Oxford University Press.
43. Lumley C. E., Walker S. R. and Hall G. C. 1986, 'The Under-Reporting of Adverse Drug Reactions Seen in General Practice', Pharmaceutical Medicine, 1, 205-212 (Pubitemid 16079336)
44. MacFarlane J. T. and Worboys M. 2007, 'The Changing Management of Acute Bronchitis in Britain, 1940-1970', Medical History, 52, 47-72.
45. Mann R. D. 1988, 'Lessons from Nomifensine', The Lancet, 24/31 December, 1490-1491 (Pubitemid 19016678)
46. Marks H. M. 1997, The Progress of Experiment, Cambridge: Cambridge University Press.
47. Moncrieff J. 2008, 'The Creation of the Concept of an Antidepressant', Social Science and Medicine, 66, 2346-2355
48. Montgomery S. A. 1982, 'The Nonselective Effect of Selective Antidepressants', in Costa E. and Racagni G. (eds.), Typical and Atypical Antidepressants, New York: Raven Press, 48-62.
49. Montgomery S., Roy D. and Montgomery D. B. 1982, 'Supersensitivity and Nomifensine in Depressed Patients', in Costa E. and Racagni G. (eds), Typical and Atypical Antidepressants, New York: Raven Press, 213-221
50. Moore T. J. 1995, Deadly Medicine, New York: Simon and Schuster.
51. Nielsen J. L., Lund N. O., Ebert-Petersen F. and Liisberg P. 1981, 'Drug Fever During Treatment with Nomifensine', Ugeskrift For Laeger, 143, 1328-1329
52. Podolsky S. H. 2006, Pneumonia before Antibiotics, Baltimore: Johns Hopkins University Press.
53. Prescott L. F., Illingworth R. N., Critchley A. J. H., Frazer J. and Stirling M. L. 1980, 'Acute Haemolysis and Renal Failure after Nomifensine Overdosage', British Medical Journal, 22 November, 281, 1392-1393 (Pubitemid 11240845)
54. Psychopharmacological Drugs Advisory Committee 1979, Transcript, PDAC, FDA, Rockville, Maryland, 15 October.
55. Quirke V. 2006, 'Putting Theory into Practice: James Black, Receptor Theory and the Development of the Beta-Blockers at ICI, 1958-1978', Medical History, 50, 69-92. (Pubitemid 44874440)
56. Rasmussen N. 2002a, 'Steroids in Arms', Medical History, 46, 299-324.
57. Rasmussen N. 2002b, 'Of "Small Men", Big Science and Bigger Business', Minerva, 40, 115-146
58. Rasmussen N. 2005, 'The Drug Industry and Clinical Research in Interwar America', Bulletin for the History of Medicine, 79, 50-80.
59. Rasmussen N. 2006, 'Making the First Anti-Depressant', Journal of the History of Medicine and Allied Sciences, 61, 288-323.
60. Salama A. and Mueller-Eckhardt C. 1985, 'The Role of Metabolite-Specific Antibodies in Nomifensine-Dependent Immune Haemolytic Anaemia', New England Journal of Medicine, 313, 469-474 (Pubitemid 15015074)
61. Sokol R. J., Hewitt S., Booker D. J., Stamps R. and Taylor M. 1985, 'Fatal Immune Haemolysis Associated with Nomifensine', British Medical Journal, 291, 311. (Pubitemid 15045114)
62. Spencer P. S. J. 1977, 'Review of the Pharmacology of Existing Anti-depressants', British Journal of Clinical Pharmacology, 4, 57S-68S.
63. Stonier P. D. 2001, 'Nomifensine and Haemolytic Anaemia-Experience of a Post-Marketing Alert', Unpublished Report.
64. Temple R. J. 1984a, FDA Approvable Letter from Director, Office of Drug Research and Review to Hoescht-Roussel, 31 December.
65. Temple R. J. 1984b, FDA Memo, 'Nomifensine', from Director, Office of Drug Research and Review to Director, Division of Neuropharmacological Drug Products, 27 July.
66. Temple R. J. 1984c, FDA Approvable Letter from Director, Office of Drug Research and Review to Hoescht-Roussel, 1 August.
67. Thomsen F., Jensen H. C. and Thomsen P. 1981, 'Liver Damage after Nomifensine', Ugeskrift For Laeger, 143, 1331-1332
68. US Congress 1986, 'Oversight of the New Drug Review Process', Hearings before a Subcommittee of the Committee on Government Operations. House of Representatives 99th Congress, 22 May, Washington: US GPO.
69. US Congress 1987, Fifteenth Report, Committee on Government Operations, 'FDA's Regulation of the New Drug Merital', 8 July, Washington: US GPO.
70. Vos R. 1991, Drugs Looking for Diseases, Dordrecht: Kluwer.
71. Waelti M. 1982, Letter from Dr Waelti to Hoescht(AG), 10 May.
72. Waelti M., Neftel K., Cohen M., de Weck A. I. and Perisie M. 1983, 'Detection of Drug-Specific IgE and IgG Antibodies using RJA: Clinical Relevance as Illustrated for Nomifensine', Schweizerische Medizinische Wochenschrift, 113, 1865-1867
73. Watkins E. S. 1998, On the Pill: A Social History of Oral Contraceptives, 1950-1970, Baltimore: Johns Hopkins University Press.
74. Wiehe P., Thybo S. and Magnussen P. 1981, 'Drug Fever Due to a New Antidepressant, Nomifensine', Ugeskrift For Laeger, 143, 1330-1331
75. Wolf M. D. 1977, Letter from Dr Wolf, Hannover, to Hoescht(AG), Frankfurt, 2 December.